한글목차

암 바이오마커 검사 세계 시장은 2024년에 248억 6,000만 달러에 달했습니다. 2033년에는 677억 4,000만 달러에 달할 것으로 예측되며, 예측 기간인 2025년까지 연평균 11.5% 성장할 것으로 예상됩니다.

암 바이오마커 검사는 암의 존재와 진행을 나타내는 생물학적 마커를 분석합니다. 바이오마커에는 암세포나 암에 반응하여 체내에서 생성되는 단백질, 유전자, 기타 물질이 포함됩니다. 암 바이오마커 검사의 주요 용도는 조기 발견, 진단, 예후 예측, 치료 효과 평가입니다.

환자의 암에 특이적인 바이오마커를 확인함으로써 보다 맞춤화된 치료 계획을 세우고, 가장 효과적인 치료법을 선택할 수 있습니다. 바이오마커 검사는 진단 정확도 향상, 치료법 선택 지침, 암 재발 징후 모니터링에 매우 중요합니다.

시장 역학:

성장 촉진요인과 억제요인

암 발병률 상승

의료 시스템이 조기 발견, 맞춤 치료, 지속적인 모니터링 개선에 초점을 맞추면서 암 발병률 증가는 암 바이오마커 검사 시장의 성장을 크게 견인할 것으로 예상됩니다. 전 세계 암 환자 수가 증가함에 따라 암을 조기에 발견하고 치료 가능한 단계에서 암을 식별하여 환자의 예후를 개선할 수 있는 정밀한 진단 도구에 대한 수요가 크게 증가하고 있습니다. 예를 들어, 국제암연구소에 따르면 2022년 폐암은 146만 건이 새로 진단될 것으로 예상되고 있습니다. 전립선암의 신규 환자 수는 2025년 313만 명에 달할 것으로 예상되고 있습니다. 암 환자 수가 증가함에 따라 다양한 바이오마커에 대한 수요가 증가할 것으로 예상됩니다.

바이오마커 검사는 표적 치료를 가능하게 하고, 시행착오적인 치료법을 줄이고 부작용을 최소화합니다. 또한, 유전체 연구의 발전과 함께 정밀의료의 중요성이 강조되면서 바이오마커 검사가 더욱 친숙하고 효과적인 검사로 자리 잡아가고 있습니다. 전 세계적으로 암 발병률이 증가함에 따라 의료 제공업체와 연구자들은 치료를 조정하고 환자 치료를 개선하기 위해 바이오마커 검사를 채택하는 경향이 증가하고 있으며, 이는 시장 확대에 박차를 가하고 있습니다.

고가의 바이오마커 검사 비용

암 바이오마커 검사는 비용이 많이 들기 때문에 특히 자원이 한정된 환경에서는 이러한 기술의 보급에 큰 걸림돌로 작용하고 있습니다. 이러한 검사는 종종 최첨단 기술과 전문 지식에 의존하는 경우가 많으며, 이로 인해 가격이 치솟고 있습니다. 가뜩이나 예산의 제약에 시달리고 있는 의료 시스템에서 바이오마커 검사를 일상적인 진료에 통합하는 것은 재정적으로 어려운 결정입니다. 이러한 경제적 장벽은 조기 발견과 맞춤 치료의 접근성을 제한할 뿐만 아니라, 전 세계적으로 암 치료에 대한 공평한 접근성을 보장하기 위해 보다 합리적인 가격의 솔루션이 필요하다는 점을 강조합니다.

목차

제1장 분석 방법이및 분석 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 전략적 인사이트와 업계 전망

• 시장 리더와 선구자
  • 새로운 선구자와 주요 기업
  • 최대 판매를 자랑하는 브랜드를 확립한 리더
  • 확립된 제품을 보유한 시장 리더
• CXO 시점
• 최신 개발과 Break through
• 사례 연구/진행 중인 연구
• 규제와 상환 상황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• Porter의 Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진입 및 확장을 위한 추천 전략
• 시나리오 분석 : 베스트 케이스/베이스 케이스/워스트 케이스 예측
• 가격 분석과 가격 시장 역학
• KOL(Key Opinion Leader)

제6장 검사 유형별

• 유전자 바이오마커 검사
• 단백질 바이오마커 검사
• 순환 종양 DNA(ctDNA) 검사
• 중합효소 연쇄반응(PCR)
• 차세대 시퀀싱(NGS)
• 기타

제7장 제품 유형

• 장비
  • PCR(중합효소 연쇄반응) 장비
  • 차세대 시퀀싱(NGS) 플랫폼
  • 질량 분석계
  • ctDNA(순환 종양 DNA) 감지 장비
  • 기타
• 키트 및 시약

제8장 암 유형별

• 폐암
• 전립선암
• 유방암
• 백혈병
• 기타

제9장 용도별

• Drug Discovery & Development
• 질환 스크리닝
• 치료 계획
• 기타

제10장 지역별

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시장 현황 및 점유율 분석
• 인수합병(M&A) 분석

제12장 기업 개요

• F. Hoffmann-La Roche Ltd
  • 기업 개요
  • 제품 포트폴리오
    • 제품 설명
    • 제품 핵심성과지표(KPI)
    • 제품 판매 실적과 예측
    • 제품 판매량
  • 재무 개요
    • 기업 매출
    • 매출 점유율 : 지역별
    • 매출 예측
  • 주요 발전
    • 인수합병(M&A)
    • 주요 제품 개발 활동
    • 규제기관 승인 등
  • SWOT 분석
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Guardant Health
• Agilent Technologies, Inc.
• Quanterix
• Exact Sciences Corporation
• QIAGEN
• Takara Bio Inc.

제13장 부록

영문목차

The global cancer biomarker testing market reached US$24.86 billion in 2024 and is expected to reach US$67.74 billion by 2033, growing at a CAGR of 11.5% during the forecast period 2025-2033.

Cancer biomarker testing analyzes biological markers that indicate the presence or progression of cancer. These biomarkers can include proteins, genes, or other substances produced by cancer cells or by the body in response to cancer. The primary applications of cancer biomarker testing are early detection, diagnosis, prognosis prediction, and assessing how well treatments are working.

Identifying specific biomarkers in a patient's cancer enables more personalized treatment plans, ensuring that the most effective therapies are selected. Biomarker testing is crucial for enhancing diagnosis accuracy, guiding treatment choices, and monitoring for any signs of cancer recurrence.

Market Dynamics: Drivers & Restraints

Rising Incidence of Cancer

The rising incidence of cancer is expected to significantly drive the growth of the cancer biomarker testing market as healthcare systems focus on improving early detection, personalized treatment, and ongoing monitoring. With an increasing number of cancer cases worldwide, there is a huge demand for precise diagnostic tools that can identify cancer at earlier, more treatable stages, enabling better patient outcomes. For instance, according to the International Agency for Research on Cancer, in 2022 there were 1.46 million new lung cancer cases diagnosed. The number of new prostate cancer cases is expected to reach 3.13 million in 2025. With the growing number of cancer cases, the demand for different biomarkers is expected to grow.

Biomarker testing allows for targeted therapies, reducing trial-and-error treatment methods and minimizing side effects, which is particularly important as cancer treatments become more complex. Additionally, the growing emphasis on precision medicine, along with advancements in genomic research, is making biomarker testing more accessible and effective. As the global cancer burden rises, healthcare providers and researchers are increasingly adopting biomarker testing to tailor treatments and improve patient care, fueling market expansion.

High Costs of Biomarker Tests

The high costs of cancer biomarker tests present a significant challenge to the widespread adoption of these technologies, particularly in resource-limited settings. These tests often rely on cutting-edge technologies and specialized expertise, driving up their price. For healthcare systems already struggling with budget constraints, integrating biomarker testing into routine care becomes a difficult financial decision. This economic barrier not only limits the availability of early detection and personalized treatment but also underscores the need for more affordable solutions to ensure equitable access to cancer care globally.

Segment Analysis

The global cancer biomarker testing market is segmented based on the test type, product type, cancer type, application, and region.

Next-generation sequencing (NGS) platforms are expected to dominate the cancer biomarker testing market.

Next-generation sequencing (NGS) refers to advanced sequencing technologies that allow for high-throughput, rapid, and cost-effective analysis of entire genomes or targeted regions of interest. In cancer biomarker testing, NGS has become a critical tool due to its ability to provide deep insights into the genetic makeup of tumors, enabling more precise detection, diagnosis, and treatment strategies.

Next-generation sequencing (NGS) platforms are poised to dominate the cancer biomarker testing market due to their unparalleled ability to provide comprehensive and high-throughput genomic insights. Several advanced next-generation sequencing tests and platforms are being introduced and research is advancing in improving these solutions to detect the cancers. For instance, in October 2024, NeoGenomics, Inc. launched its AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).

This capability significantly enhances early cancer detection, prognosis prediction, and monitoring of treatment responses. As the demand for precision medicine grows, NGS platforms are increasingly favored for their accuracy, scalability, and versatility, positioning them in a significant position in the market share.

Geographical Analysis

North America is expected to dominate the cancer biomarker testing market

North America holds a dominant position in the cancer biomarker testing market, driven by its sophisticated healthcare infrastructure and substantial investments in research and development. The region's access to cutting-edge technologies, including Next-Generation Sequencing (NGS) and liquid biopsy, accelerates the integration of advanced cancer biomarker testing into clinical practice.

The region's growth in the market is further enhanced by the presence of leading biotechnology and pharmaceutical companies, which are at the forefront of innovating and commercializing new biomarker tests, propelling market growth.

Moreover, North America's strong emphasis on precision medicine and personalized treatment further boosts demand for cancer biomarker testing, as it plays a crucial role in tailoring therapies to individual patients. The rising cancer incidence, coupled with an increasing focus on early detection and public awareness, has created a significant need for reliable diagnostic tools.

Competitive Landscape

The global market players in the cancer biomarker testing market are F. Hoffmann-La Roche Ltd, Illumina, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Guardant Health, Agilent Technologies, Inc., Quanterix, Exact Sciences Corporation, QIAGEN and Takara Bio Inc., among others.

Key Developments

• In August 2024, Illumina, Inc. received Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications.
• In April 2024, Takara Bio USA, Inc. launched its Shasta Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cancer biomarker testing market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Test Type
• 3.2. Snippet by Product Type
• 3.3. Snippet by Cancer Type
• 3.4. Snippet by Application
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Incidence of Cancer
    • 4.1.1.2. Advances in Genomic and Molecular Research
  • 4.1.2. Restraints
    • 4.1.2.1. High Costs of Biomarker Tests
    • 4.1.2.2. Regulatory and Approval Challenges
  • 4.1.3. Opportunities
    • 4.1.3.1. Integration of Cancer Biomarker Testing with Liquid Biopsy for Monitoring
  • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with the largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Test Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 6.1.2. Market Attractiveness Index, By Test Type
• 6.2. Genetic Biomarker Testing*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Protein Biomarker Testing
• 6.4. Circulating Tumor DNA (ctDNA) Testing
• 6.5. Polymerase Chain Reaction (PCR)
• 6.6. Next-Generation Sequencing (NGS)
• 6.7. Others

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Instruments*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. PCR (Polymerase Chain Reaction) Machines
  • 7.2.4. Next-Generation Sequencing (NGS) Platforms
  • 7.2.5. Mass Spectrometers
  • 7.2.6. ctDNA (Circulating Tumor DNA) Detection Devices
  • 7.2.7. Others
• 7.3. Kits & Reagents

8. By Cancer Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 8.1.2. Market Attractiveness Index, By Cancer Type
• 8.2. Lung Cancer*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Prostate Cancer
• 8.4. Breast Cancer
• 8.5. Leukemia
• 8.6. Others

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Drug Discovery and Development*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Disease Screening
• 9.4. Treatment Planning
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. Latin America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Mexico
    • 10.4.7.3. Argentina
    • 10.4.7.4. Rest of Latin America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. F. Hoffmann-La Roche Ltd*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Illumina, Inc.
• 12.3. Thermo Fisher Scientific Inc.
• 12.4. Bio-Rad Laboratories, Inc.
• 12.5. Guardant Health
• 12.6. Agilent Technologies, Inc.
• 12.7. Quanterix
• 12.8. Exact Sciences Corporation
• 12.9. QIAGEN
• 12.10. Takara Bio Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us